slides · global inventory
Image
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 119,566
Current window 67,111-67,140
Pages 3,986
Rows per page 30
Component
67,111-67,140 of 119,566
38
The slide uses an excerpt from the FDA label to critique the clinical trial design.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
47
The slide uses screenshots of social media posts as primary evidence to challenge the clinical narrative.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
48
The slide uses a specific chart from a clinical paper to challenge the safety profile of the drug.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
49
Uses a red-annotated chart to highlight the discrepancy between reported LBM and suspected fluid retention.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
50
Includes links to cached PDF documents as evidence of data discrepancy.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
108
The slide uses a screenshot of an FDA Medication Guide to contrast with the claim that DKA is missing from clinical literature.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
113
The slide is a reproduction of a scientific poster (Gevers et al., 2024) used as evidence for clinical trial outcomes.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
126
The slide uses a direct quote from a conference abstract to highlight a discrepancy between the reported 60% figure and the author's own analysis.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
127
The slide uses a red box to highlight specific text in the source material to support the claim of burying data.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
144
The slide uses a medical illustration to show the impact of fluid retention on heart chambers (diastolic vs systolic).Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
145
The slide uses red annotations to re-interpret the company's original chart data.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
146
The slide uses a technical explanation of DEXA limitations to undermine the company's reported clinical trial results.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
149
The slide uses red boxes to highlight specific text in the protocol that contradicts the lack of reporting in the final study.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
157
Uses social media follower counts as a proxy for community size to highlight the lack of engagement with the drug.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
159
The slide uses a specific Facebook post as a case study to contradict the product's efficacy claims.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
160
The slide uses screenshots of Facebook comments to build a case against the drug's efficacy and safety profile.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
162
The slide uses screenshots of Facebook posts to provide qualitative evidence of patient dissatisfaction and safety concerns.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
163
The slide uses direct quotes from Facebook groups to build a case against the drug's efficacy/safety profile.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
164
The slide uses screenshots of Facebook comments to illustrate the divide between frustrated participants and those defending the study.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
165
The slide uses social media screenshots to establish a pattern of adverse events.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
166
The slide uses anecdotal evidence from Facebook discussion groups to highlight potential adverse drug reactions.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
167
The slide uses screenshots of Facebook group posts to provide anecdotal evidence of drug side effects.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
168
The slide uses patient testimonials to contradict the safety profile of the drug Vykat.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
169
The slide uses direct quotes from Facebook discussion groups to build a case against the drug's safety profile.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
170
The slide uses direct quotes from a Facebook discussion group to highlight a patient/caregiver pain point regarding medical monitoring.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
171
The slide uses anecdotal evidence from Facebook groups to challenge the safety profile of the drug Vykat.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
172
The slide uses anecdotal evidence from Facebook groups to challenge the safety profile of the drug Vykat.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
173
The slide uses anecdotal evidence from social media to undermine the perceived value of the drug.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
174
The slide uses anecdotal evidence from Facebook groups to argue against the efficacy of a treatment by highlighting inconsistencies in user reports.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
175
The slide presents a skeptical analysis of patient/parent testimonials to undermine the perceived efficacy of a drug.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit